Sanofi (NASDAQ:SNY) Shares Purchased by Oxbow Advisors LLC

Oxbow Advisors LLC grew its position in Sanofi (NASDAQ:SNY - Free Report) by 4.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 104,749 shares of the company's stock after acquiring an additional 4,790 shares during the period. Oxbow Advisors LLC's holdings in Sanofi were worth $5,052,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in SNY. Charles Schwab Investment Management Inc. increased its holdings in shares of Sanofi by 31.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company's stock valued at $8,040,000 after purchasing an additional 33,105 shares in the last quarter. Arkadios Wealth Advisors lifted its position in shares of Sanofi by 19.0% during the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock valued at $227,000 after acquiring an additional 751 shares during the period. Geode Capital Management LLC boosted its stake in shares of Sanofi by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after acquiring an additional 16,780 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock worth $133,172,000 after acquiring an additional 399,301 shares during the period. Finally, GFS Advisors LLC raised its holdings in Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company's stock worth $738,000 after purchasing an additional 11,655 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of SNY traded up $0.06 during trading hours on Wednesday, reaching $54.95. 1,823,142 shares of the company traded hands, compared to its average volume of 2,414,638. The stock has a market capitalization of $139.45 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The stock has a fifty day simple moving average of $51.22 and a 200 day simple moving average of $52.56. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on SNY. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.